TCON has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
TCON has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
TRACON Pharmaceuticals's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2024 was $0.00 Mil. TRACON Pharmaceuticals's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2024 was $0.00 Mil. TRACON Pharmaceuticals's Total Stockholders Equity for the quarter that ended in Jun. 2024 was $-3.09 Mil. TRACON Pharmaceuticals's debt to equity for the quarter that ended in Jun. 2024 was 0.00.
A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.
The historical rank and industry rank for TRACON Pharmaceuticals's Debt-to-Equity or its related term are showing as below:
During the past 12 years, the highest Debt-to-Equity Ratio of TRACON Pharmaceuticals was 2.11. The lowest was -3.45. And the median was 0.26.
The historical data trend for TRACON Pharmaceuticals's Debt-to-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TRACON Pharmaceuticals Annual Data | |||||||||||||||||||||
Trend | Dec14 | Dec15 | Dec16 | Dec17 | Dec18 | Dec19 | Dec20 | Dec21 | Dec22 | Dec23 | |||||||||||
Debt-to-Equity | Get a 7-Day Free Trial | 2.11 | 0.18 | 0.13 | -1.40 | -0.29 |
TRACON Pharmaceuticals Quarterly Data | ||||||||||||||||||||
Sep19 | Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | Mar24 | Jun24 | |
Debt-to-Equity | Get a 7-Day Free Trial | - | - | -0.29 | - | - |
For the Biotechnology subindustry, TRACON Pharmaceuticals's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, TRACON Pharmaceuticals's Debt-to-Equity distribution charts can be found below:
* The bar in red indicates where TRACON Pharmaceuticals's Debt-to-Equity falls into.
Debt to Equity measures the financial leverage a company has.
TRACON Pharmaceuticals's Debt to Equity Ratio for the fiscal year that ended in Dec. 2023 is calculated as
Debt to Equity | = | Total Debt | / | Total Stockholders Equity | ||
= | (Short-Term Debt & Capital Lease Obligation | + | Long-Term Debt & Capital Lease Obligation) | / | Total Stockholders Equity | |
= | (0.236 | + | 0) | / | -0.809 | |
= | -0.29 |
TRACON Pharmaceuticals's Debt to Equity Ratio for the quarter that ended in Jun. 2024 is calculated as
Debt to Equity | = | Total Debt | / | Total Stockholders Equity | ||
= | (Short-Term Debt & Capital Lease Obligation | + | Long-Term Debt & Capital Lease Obligation) | / | Total Stockholders Equity | |
= | (0 | + | 0) | / | -3.089 | |
= | 0.00 |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TRACON Pharmaceuticals (OTCPK:TCON) Debt-to-Equity Explanation
In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.
Be Aware
Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.
Thank you for viewing the detailed overview of TRACON Pharmaceuticals's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.
Opaleye Management Inc. | 10 percent owner | ONE BOSTON PLACE, SUITE 2600, BOSTON MA 02108 |
Charles Theuer | director, officer: President and CEO | C/O TRACON PHARMACEUTICALS, INC., 4350 LA JOLLA VILLAGE DRIVE, SUITE 800, SAN DIEGO CA 92122 |
Bonne J. Adams | officer: Chief Operating Officer | C/O TRACON PHARMACEUTICALS, INC., 4350 LA JOLLA VILLAGE DRIVE, SUITE 800, SAN DIEGO CA 92122 |
Scott B. Brown | officer: Chief Accounting Officer (PAO) | C/O TRACON PHARMACEUTICALS, INC., 4350 LA JOLLA VILLAGE DRIVE, SUITE 800, SAN DIEGO CA 92122 |
William R Larue | director | C/O TRACON PHARMACEUTICALS, INC., 8910 UNIVERSITY CENTER LANE, SUITE 700, SAN DIEGO CA 92122 |
Carol C. Lam | director | C/O TRACON PHARMACEUTICALS, INC., 4350 LA JOLLA VILLAGE DRIVE, STE 800, SAN DIEGO CA 92122 |
Saundra L Pelletier | director | C/O EVOFEM BIOSCIENCES, INC., 12400 HIGH BLUFF DRIVE, SUITE 600, SAN DIEGO CA 92130 |
Lisa Johnson-pratt | director | C/O TRACON PHARMACEUTICALS, INC., 4350 LA JOLLA VILLAGE DRIVE, SUITE 800, SAN DIEGO CA 92122 |
Ikarian Healthcare Master Fund, L.p. | 10 percent owner, other: Member of 10% Group | 100 CRESCENT COURT, SUITE 1620, DALLAS TX 75201 |
Mark C Wiggins | officer: Chief Business Officer | 12671 HIGH BLUFF DRIVE SUITE 200, SAN DIEGO CA 92130 |
Neil Shahrestani | 10 percent owner, other: Member of 10% Group | 12806 WINDING CREEK DRIVE, FRISCO TX 75035 |
Ikarian Healthcare Fund Gp, L.p. | 10 percent owner, other: Member of 10% Group | 100 CRESCENT COURT, SUITE1620, DALLAS TX 75201 |
Chart Westcott Living Trust | 10 percent owner, other: Member of 10% Group | 100 CRESCENT COURT, SUITE1620, DALLAS TX 75201 |
Ikarian Capital, Llc | 10 percent owner, other: Member of 10% Group | 100 CRESCENT COURT, SUITE 1620, DALLAS TX 75201 |
Puissance Cross-border Opportunities V Llc | 10 percent owner | 950 THIRD AVENUE, 25TH FL, NEW YORK NY 10022 |
From GuruFocus
By GuruFocus Research • 02-09-2024
By GuruFocus Research • 02-09-2024
By GuruFocus Research • 02-09-2024
By GuruFocus Research • 02-09-2024
By GuruFocus Research • 02-09-2024
By GuruFocus Research • 02-09-2024
By Marketwired • 07-01-2024
By Marketwired • 07-30-2024
By GuruFocus Research • 02-09-2024
By GuruFocus Research • 05-15-2024
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.